𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of thrombotic thrombocytopenic purpura: A role for early vincristine administration

✍ Scribed by Catherine Mazzei; Samuel Pepkowitz; Ellen Klapper; Dennis Goldfinger


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
23 KB
Volume
13
Category
Article
ISSN
0733-2459

No coin nor oath required. For personal study only.

✦ Synopsis


Plasma exchange (PE) is considered first-line treatment for thrombotic thrombocytopenic purpura (TTP) to the point that many clinicians regard it as definitive therapy. Studies have reported response rates to PE ranging from 39% to 78%. In our experience, a minority of patients have been cured solely by PE. While adjuvant therapies (e.g., vincristine, splenectomy) have proved effective in anecdotal reports, protocols using these therapies in the treatment of TTP have not been established.

Management of TTP over a 15-year period was reviewed to evaluate (1) the rate of cure accomplished by PE alone, and (2) the potential benefit of additional therapies. The records of 29 consecutive patients with TTP treated by PE were reviewed and classified according to response to PE alone and the need for adjuvant therapy.

Eight patients (28%) achieved remission and long-term survival with PE alone. With the addition of adjuvant therapy another 13 patients survived, bringing the total survival to 72%. Fifteen patients were treated with vincristine in addition to PE. Only three of seven patients receiving vincristine after failing to respond completely to PE survived, but survival increased to 88% (7 of 8) when vincristine was administered within 3 days of beginning PE.

These data suggest that PE alone may not be sufficient therapy for most patients with TTP. Additional therapy is often needed to achieve long-term survival. While controlled trials will be necessary to prove the efficacy of vincristine, we believe that, given the minimal risk of vincristine toxicity and the grave consequences of ineffective therapy, routine administration of vincristine early in the course of PE should be considered.


πŸ“œ SIMILAR VOLUMES


Rituximab for treatment of refractory/re
✍ Afaq Ahmad; Anita Aggarwal; Daya Sharma; Harish P. Dave; Virginia Kinsella; Marg πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 112 KB πŸ‘ 2 views

## Abstract Plasma exchange is the standard treatment for thrombotic thrombocytopenic purpura (TTP). For patients refractory to plasma exchange, treatment options are limited and often unsuccessful. The platelet thrombi that form in acquired TTP are believed to result from the presence of procoagul

Treatment of plasma refractory thromboti
✍ Gaddis, Thomas G.; Guthrie, Troy H.; Drew, Mary Jo; Sahud, Mervyn; Howe, Robert πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 37 KB πŸ‘ 1 views

The objective of this study was to assess the effect of protein A immunoabsorption in terms of response rate and toxicities in patients with classical thrombotic thrombocytopenic purpura (TTP) refractory to therapeutic plasma exchange. The study included nine females and one male with a diagnosis of

Rituximab for the treatment of refractor
✍ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp